Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast CancerJude M. Mulligan, Richard D. Kennedy, Jacqueline A. James et al.|JNCI Journal of the National Cancer Institute|2014Cited by 127
Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancerPeter Bankhead, Peter W. Hamilton, José A. Fernández et al.|Laboratory Investigation|2017Cited by 122
The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancerDavid P. Boyle, Manuel Salto‐Tellez, Darragh G. McArt et al.|Histopathology|2014Cited by 67
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast CancerMatthew P. Humphries, Niamh E. Buckley, Seán O. Hynes et al.|Journal of Oncology|2018Cited by 63
Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpressionJonathan Stewart, Manuel Salto‐Tellez, Jacqueline A. James et al.|Modern Pathology|2014Cited by 30